Barclays analyst Peter Lawson reiterated an Underweight rating and $1.00 price target on Adaptimmune Therapeutics plc (NASDAQ: ADAP).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE